Humulin M3 (Insulin Human (Rdna))

Humulin M3 is prescribed for the treatment of diabetes mellitus when insulin replacement is needed.

• To provide basal insulin coverage for individuals with type 1 diabetes.
• To supply prandial (mealtime) insulin in patients with type 2 diabetes.
• As a component of intensive insulin regimens together with rapid‑acting or long‑acting insulin analogues.
• For use in children and adolescents who require insulin therapy.
• When flexible dosing schedules are required to match carbohydrate intake and activity levels.
• To replace endogenous insulin production in patients who have undergone total pancreatectomy.

• Humulin M3 contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor binding activates intrinsic tyrosine‑kinase activity, initiating a cascade that promotes translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake. In the liver, the signal suppresses gluconeogenesis and glycogenolysis, thereby lowering circulating glucose. The overall effect is a rapid reduction in blood‑sugar levels that mimics physiological insulin action.

Adverse reactions to Humulin M3 may occur, ranging from mild to severe. The most frequently reported events are listed under common, while serious events are less common but require immediate medical attention.

Common

• Hypoglycemia (low blood glucose)
• Injection‑site pain, redness or swelling
• Lipodystrophy (localized fat loss or accumulation)
• Weight gain
• Itching or rash at the injection site
• Transient blurred vision
• Nausea or vomiting

Serious

• Severe hypoglycemia with loss of consciousness
• Anaphylactic or severe allergic reaction
• Hypokalemia (low potassium)
• Pulmonary edema or fluid retention
• Necrotizing fasciitis at injection site (rare)
• Seizures secondary to severe hypoglycemia
• Acute coronary syndrome in patients with pre‑existing heart disease

When using Humulin M3, certain precautions should be observed to minimize risks and ensure safe therapy.

• Verify blood glucose levels before each injection to avoid hypoglycemia.
• Adjust dose during periods of illness, fasting, or increased physical activity.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Monitor for signs of allergic reactions, especially after the first few doses.
• Do not use in individuals with known hypersensitivity to human insulin or any excipients.
• Pregnant or breastfeeding women should consult a healthcare professional before initiating therapy.
• Store the product according to the label and discard after the recommended in‑use period.

Humulin M3 may interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use of other rapid‑acting insulin analogues without dose adjustment.
• Beta‑blockers that mask hypoglycemia symptoms.
• High‑dose corticosteroids that raise blood glucose markedly.
• MAO‑inhibitors that can potentiate insulin’s effect.
• Thiazide diuretics that may increase blood glucose.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• ACE inhibitors or ARBs, which may enhance insulin sensitivity.
• Diuretics that affect potassium balance.
• Alcohol consumption, which can cause delayed hypoglycemia.
• Thyroid hormones, which may alter insulin requirements.